[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
Titel:
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
Auteur:
Singh, Simron Halperin, Daniel Myrehaug, Sten Herrmann, Ken Pavel, Marianne Kunz, Pamela L Chasen, Beth Tafuto, Salvatore Lastoria, Secondo Capdevila, Jaume García-Burillo, Amparo Oh, Do-Youn Yoo, Changhoon Halfdanarson, Thorvardur R Falk, Stephen Folitar, Ilya Zhang, Yufen Aimone, Paola de Herder, Wouter W Ferone, Diego